Ligand Pharmaceuticals (LGND) Business Metric Overview - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Ligand Pharmaceuticals

    NASDAQ: LGND · Real-Time Price · USD
    165.86
    -0.89 (-0.53%)
    At close: Sep 08, 2025, 3:59 PM
    165.86
    0.00%
    After-hours: Sep 08, 2025, 04:40 PM EDT

    Ligand Pharmaceuticals Revenue Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Jun 30, 2018 Mar 31, 2018
    Evomela Revenue 1.47M 1.98M 8.29M 1.75M 2.73M 1.4M 3.92M 2.5M 2.36M 2.55M 26.88M 3.12M 2.39M 2.7M 35.38M 2.67M 2.19M 2.33M 86.57M 1.8M 1.2M 1.58M 7.61M 20.8M
    Evomela Revenue Growth -26.05% -76.10% +374.36% -36.08% +95.63% -64.38% +57.07% +5.94% -7.57% -90.51% +760.68% +30.45% -11.37% -92.36% +1227.43% +21.52% -6.00% -97.31% +4704.11% +50.29% -23.92% -79.30% -63.40% n/a
    Financial Royalty Assets Revenue 6.31M 5.9M 68.78M 5.16M 559K 738K 22.46M 10.54M 8.1M 6.23M 21.04M 9.12M 7.13M 4.62M 17.55M 8.82M 5.44M 4.29M n/a 6.92M 5.48M 4.41M n/a 4.39M
    Financial Royalty Assets Revenue Growth +6.96% -91.42% +1233.66% +822.54% -24.25% -96.71% +113.18% +30.13% +30.01% -70.39% +130.58% +28.01% +54.20% -73.67% +98.97% +62.15% +26.90% n/a n/a +26.31% +24.43% n/a n/a n/a
    Intangible Royalty Assets Revenue 30.08M 21.59M 24.63M 26.55M 22.6M 18.36M n/a 8.61M 5.22M 10.62M n/a 35.95M 29.55M 12.12M n/a 35.09M 62.51M 31.27M n/a 23.39M 7.18M 6.57M n/a n/a
    Intangible Royalty Assets Revenue Growth +39.36% -12.35% -7.25% +17.47% +23.13% n/a n/a +64.90% -50.86% n/a n/a +21.68% +143.73% n/a n/a -43.86% +99.89% n/a n/a +225.71% +9.38% n/a n/a n/a
    Kyprolis Revenue 8.8M 4.72M 77.06M 11.6M 9M 6.63M n/a 23.86M 20.43M 17.15M n/a 19.84M 17.96M 13.7M n/a 15.65M 8.62M 7.11M n/a 9.01M n/a n/a n/a n/a
    Kyprolis Revenue Growth +86.39% -93.87% +564.40% +28.91% +35.68% n/a n/a +16.80% +19.10% n/a n/a +10.46% +31.14% n/a n/a +81.62% +21.15% n/a n/a n/a n/a n/a n/a n/a
    Material Sales, Captisol Revenue 8.29M 13.46M n/a 6.25M 7.5M 9.21M n/a 3.68M 3.03M 2.61M n/a 2.1M 2.32M 1.65M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Material Sales, Captisol Revenue Growth -38.43% n/a n/a -16.60% -18.58% n/a n/a +21.47% +16.06% n/a n/a -9.41% +40.51% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Royalty Revenue 36.4M 27.49M n/a 31.71M 23.16M 19.09M n/a 2.8M 3.61M 3.5M n/a 4.07M 5.5M 2.91M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Royalty Revenue Growth +32.41% n/a n/a +36.90% +21.30% n/a n/a -22.50% +3.23% n/a n/a -26.01% +89.01% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Rylaze Revenue 2.86M 3.12M n/a 3.89M 3.23M 2.95M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Rylaze Revenue Growth -8.18% n/a n/a +20.24% +9.49% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Teriparatide Injection Revenue 2.3M 1.19M n/a 2.38M 2.1M 2.04M n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
    Teriparatide Injection Revenue Growth +92.95% n/a n/a +12.98% +3.04% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

    Operating Expense Breakdown

    Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
    Selling, General, and Administrative Revenue 20.18M 18.8M 25.61M 24.48M 17.62M 10.95M 15.99M 14.66M 11.29M 10.86M 31.13M 17.45M 14.59M 18.18M 17.74M 12.72M 14.71M 12.62M 30.08M 15.02M 10.07M 9.26M 10.28M 9.53M 10.99M 11.09M 11.16M 9.63M 9.29M 7.64M 7.75M 7.03M 6.55M 7.32M 6.63M 6.3M 6.86M 6.83M 6.19M 4.97M 7.22M 5.99M
    Selling, General, and Administrative Revenue Growth +7.31% -26.57% +4.62% +38.88% +60.93% -31.52% +9.12% +29.85% +3.98% -65.13% +78.45% +19.61% -19.77% +2.50% +39.46% -13.55% +16.60% -58.06% +100.28% +49.17% +8.69% -9.86% +7.90% -13.36% -0.85% -0.67% +15.88% +3.65% +21.60% -1.37% +10.20% +7.38% -10.56% +10.50% +5.09% -8.13% +0.56% +10.26% +24.52% -31.20% +20.54% n/a
    Research and Development Revenue 6.57M 50.09M 4.42M 5.67M 5.35M 5.97M 5.49M 5.53M 6.85M 6.66M 9.2M 22.04M 19.12M 20.31M 18.24M 16.94M 15.95M 17.88M 21.92M 12.85M 12.73M 11.89M 18.66M 13.74M 12.21M 11.29M 8.84M 5.48M 6.13M 7.41M 8.63M 4.76M 4.82M 8.67M 6.41M 6.3M 4.51M 4M 2.87M 2.54M 4.01M 3.96M
    Research and Development Revenue Growth -86.89% +1031.86% -22.03% +6.00% -10.33% +8.80% -0.80% -19.29% +2.87% -27.55% -58.26% +15.26% -5.86% +11.31% +7.70% +6.17% -10.77% -18.42% +70.51% +0.95% +7.07% -36.29% +35.82% +12.52% +8.18% +27.70% +61.23% -10.63% -17.17% -14.20% +81.40% -1.31% -44.40% +35.35% +1.63% +39.89% +12.56% +39.51% +13.08% -36.71% +1.21% n/a

    Add to Watchlist